Robert Lutz
Chief Scientific Officer Iksuda Therapeutics
Seminars
Thursday 5th November 2026
Defining the Next Era of ADC Payload Revolution From Proven Mechanisms to Transformative Innovation
9:00 am
- Examine why continued reliance on tubulin and topoisomerase payloads is becoming strategically and clinically unsustainable, as hundreds of ADCs with the same mechanisms move into the clinic and patient populations become saturated and resistant
- Provide a reality‑based assessment of which novel payload classes are genuinely close to clinical readiness, separating mechanisms with real translational momentum from those that remain conceptual
- Argue why the ADC field is at an inflection point, where measured rule‑breaking and early risk‑taking on novel payloads is now required to avoid long‑term stagnation
